Akèy › Leksemi biphenotipik egi › Michigan
Etid klinik pou Leksemi biphenotipik egi nan Michigan
4 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- ak 2 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- ak 2 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- C.S. Mott Children's Hospital, Ann Arbor
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.